Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Recent advances in blood cancer treatments are offering patients safer options and longer-lasting remissions. Studies ...

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

Pfizer has shared promising phase 2 results of its Elrexfio (elranatamab-bcmm) monotherapy in patients with heavily pre-treated relapsed or refractory multiple myeloma (RRMM) as part of its ongoing ...

Recent breakthroughs in cancer research range from targeted therapies for aggressive blood cancers to national efforts aiming to eliminate cervical cancer. Studies highlight treatments that improve ...